FDA Advisors Back Novavax’s Covid Vaccine, Clearing Way for Authorization
The Food and Drug Administration’s vaccines advisory panel backed Novavax ’s long-delayed Covid-19 vaccine, saying the benefits outweighed the risks. The stock was rising 17% to $55.60 in premarket trading…